Sample Service
Recommended Information
CD4+ Naive T Cell Sorting Service
CBMC Isolation and Preparation Services
Cord blood mononuclear cells (CBMCs) are isolated from the placental and umbilical cord tissues of healthy newborns. They are nucleated cells present in umbilical cord blood and represent the largest cell population in the human body, comprising lymphocytes and monocytes. These cells constitute an essential component of the immune defense system, exerting protective and eliminative functions against invading pathogenic microorganisms through phagocytosis and antibody production.
01
Compliance Approval
02
Recruitment and Screening
03
Collect
04
Separation and preparation
05
Quality Control
06
Sample Delivery
01
Compliance Approval
02
Recruitment and Screening
03
Collect
04
Separation and preparation
05
Quality Control
06
Sample Delivery
I. Sample Introduction:
Umbilical cord blood mononuclear cells (CBMC) Cord Blood Mononuclear Cells are isolated from the placental and umbilical cord tissues of healthy individuals; they are mononuclear cells present in umbilical cord blood and represent the largest cell type in the human body. Including lymphocytes and monocytes, they constitute an important component of the body’s defense system, combating and eliminating invading pathogenic microorganisms through phagocytosis and antibody production, among other mechanisms.

What are the advantages of umbilical cord blood mononuclear cells?
1. Umbilical cord blood Widely sourced and easy to collect, It will cause no harm to the donor;
2. Hematopoietic stem/progenitor cells in cord blood are more primitive, Strong proliferative and differentiative capacity;
3. Umbilical cord blood mononuclear cells, whether primary, passaged, differentiated, or treated with IFN-γ (*interferon, a class of secreted proteins with broad-spectrum antiviral, antitumor, and immunomodulatory activities), All exhibit relatively weak cellular immunogenicity. , thereby preventing the allogeneic umbilical cord blood immune cells from eliciting an immune response in the recipient’s body. Long in vivo survival time ;
4. Non-tumorigenic : Neither in vitro nor in animal studies has any tumorigenic potential been observed for umbilical cord blood itself or for mesenchymal and endothelial cells derived from it, either in vivo or in vitro.
Therefore, umbilical cord blood mononuclear cells can be safely used as allogeneic cells.
Mononuclear cells can be used as needed. Differentiates into multiple immune cell types , expand a large number of highly active immune cells in vitro and infuse them back into the human body, No rejection or side effects , which can provide more precise solutions for critical illnesses and offer all-round protection for our health.
Delivery method:
| Sample Delivery Specification (million/instance) | Sample Delivery Format |
| 10 / 25 / 50 / 100 | Cryopreservation |
| 25 / 50 / 75 / 100 / 150 / 200 / 300 / 500 / 1000 | Fresh |
Release Criteria:
| Cell count | Cell viability | CD34+ proportion | Bacterial and Fungal Detection (PCR) |
Mycoplasma Detection (PCR) | HAV, HBV, HCV, HIV, TPAb, HTLV, EB, B19 |
| > Specification Quantity | >90% | >90% | Negative | Negative | Negative |
Service Advantages:
Quality System
1. Strict adherence to subject screening , Standards for Sample Collection and Management
2. Complete ethical approval documentation that complies with the review requirements of the ethics committee and other regulatory compliance obligations, including corporate audits, and supports on-site inspections by clients.
3. Professional Cold-Chain Logistics Cooperation system , ensuring the entire sample process Compliant and Efficient Delivery
R&D System
1. Focus in Cell therapy and Gene therapy and large-molecule drug development
2. Continuously optimize standardized preparation processes and lead industry service standards.
3. Innovate service models and expand the boundaries of research applications
Professional Team
1. A seasoned R&D team and a mature, standardized cell preparation process and manufacturing system.
2. Standardization covering both Chinese and international populations Donor Registry and management system
Core Resources
1. World-class production and service equipment, as well as laboratory facilities, nearly 1,000-square-meter R&D base
2. Establish multiple clinical collaboration centers, with the East China region as the leading hub, covering tertiary hospitals nationwide and high-quality GCP management centers.
3. Our in-house specialized project team can provide clients with services such as regulatory interpretation, policy analysis, domestic-investor qualification determination, and approval for foreign-invested cooperation. , Providing one-stop compliance support
II. Sample COA:

Keyword
Previous page:
:Next page
Previous page:
Next page: